



Hui a Tau

Annual Shareholders Meeting

20 October 2026

Disclaimer and important notice

Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading distributor of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to subscribe for, or an offer of, shares, securities or financial products to any person, in any country or the basis for a contract, financial advice, other advice or recommendation to conclude any transaction for the purchase or sale of any security, loan or other instrument. This presentation has not been independently verified. Neither Rua nor any of its directors, officers, shareholders, advisors, agents or employees make any representation or warranty as to the accuracy or completeness of the information contained in this presentation and those parties shall have no liability for any statement, opinion, information or matters arising out of, contained in, or for any omissions from, or failure to correct or update any information in, this presentation or any other communications transmitted to you in relation to this presentation.

How to Participate in Virtual/ Hybrid Meetings and Ask a Question


Shareholder & Proxyholder Q & A Participation

Online Questions

If you have a question to submit during the live meeting, please select the **Q & A tab** on the right half of your screen at anytime. Type your question into the field and press submit. Your question will be immediately submitted to the moderator.

Help


The **Q & A tab** can also be used for **immediate help**. If you need assistance, please submit your query in the same manner as typing a question and a Computershare representative will respond directly to you.



How to Participate in Virtual/ Hybrid Meetings and Vote

Shareholder & Proxyholder Voting

- Once the voting has been opened, the resolutions and voting options will allow voting.
- To vote, simply click on the Vote tab, and select your voting direction from the options shown on the screen.
- Your vote has been cast when the tick appears.
- To change your vote, select 'Change Your Vote'.



Board of Directors

Te Poari Ringatohu



Anna Stove

Chair

More than 25 years' global executive and board experience across healthcare, biotechnology and regulated scientific sectors.



Panapa Ehau

Executive Director, Co-Founder

Co-founder of a number of social enterprises. Holds governance roles across numerous for-profit and charitable organisations.



Teresa Ciprian

Non-Executive Director

Global expertise in innovation, commercialisation, marketing and business development in the primary sector.



Tony Barclay

Non-Executive Director

Over 30 years' experience in business, with 25 years of healthcare experience. Chair of the Audit, Finance and Risk Committee.

Agenda

Rarangi take

01 Company overview and Chair's address

02 Chief Executive's presentation

03 Annual Results presentation


04 Shareholder questions

05 Ordinary resolutions

06 General business

Ordinary resolutions

- 1 Auditor's remuneration
- 2 Re-election of Anna Stove as Director
- 3 Re-election of Panapa Ehau as Director
- 4 Re-election of Antony Barclay as Director
- 5 Election of Qi (Keith) Zhou as Director
- 6 Issue of new Ordinary Shares (if required)

A woman with long brown hair, wearing a light-colored blazer over a white t-shirt, stands outdoors with her hands in her pockets. She is smiling at the camera. The background is a soft-focus landscape of green hills and trees under a warm, golden light, suggesting a sunset or sunrise. The overall mood is professional yet approachable.


01

Company overview and Chair's address

Te tirohanga whanui o te kamupene me te korero a te Heamana

Rua's differentiated, capital-light model

Built around unique genetics, market access and trusted partners



FY26 Key Achievements summary

Financial results and progress across our markets



Commercial momentum

\$2.9m

Total revenue +53%



Cost control

\$3.1m

Operating loss ↓7%



Shareholder support

\$2.3m

Equity raised

Commercial milestones

Customer revenue grew 71% to \$2.6m.

Czechia Rua's first product launched through partner Motagon.

Canada First live cannabis clone export — the first known legal export of live cannabis genetics from New Zealand.

Australia & New Zealand Expanded NZ product portfolio and grew sales with leading Australian clinic chains.



Subsequent activity

UK sales and distribution agreement with Curaleaf
Five further products approved in Aotearoa New Zealand

UK agreement: a significant commercial milestone

A major step forward for Rua's export-led strategy

LARGEST EXPORT AGREEMENT TO DATE

\$10m+

EXPECTED REVENUE

**over the initial
two-year term**

A significant route to market

Access to an established UK clinic and distribution channel.

Evidence of the strategy's potential

A major export opportunity delivered through Rua's capital-light model.

Working capital enables delivery

Inventory and working capital must be funded ahead of sales and cash receipts.

Approximately \$1mill raised from recent rights issue

Working capital is the immediate constraint — not infrastructure



\$1m

Rights Offer outcome

- Funds inventory and working capital ahead of sales, particularly to fulfil the UK agreement.
- Supports demand in Australia and Aotearoa, New Zealand—alongside opportunities in Canada and Czechia.

02

Chief Executive Officer's presentation

Te whakatakotoranga o te Kaiwhakahaere
Matua




FY26: An overview

Tirohanga whanui

\$2.9m

Total Revenue



71%

Revenue growth


6

Markets

Global progress

Kokiri ki te ao

Aotearoa New Zealand	Grew market share; five new product approvals
Australia	Almost doubled revenue through key clinic chains
United Kingdom	Largest export agreement to date, signed July 2026
Germany	Expanded product range at a time of market change
Canada	First export of live clones to Apollo Green
Czechia	First products launched through Motagon




Six markets, one platform

Australia | Aotearoa New Zealand | Germany | United Kingdom | Czechia | Canada



Aotearoa, New Zealand is our home market

- Revenue almost tripled to \$1.30m (FY25: \$0.44m), with increased market share.
- New products introduced, including a medical vaporising device.
- Five further products approved by the regulator in July 2026.






Australia is the second largest market

- Revenue almost doubled to \$1.03m (FY25: \$585k), with margin also almost doubling.
- World's second largest medicinal cannabis market, estimated at \$1.4b.
- Grew market share through strong clinic chain relationships, despite the regulator's review.

Sales revenue





Germany is the largest market

- World's largest market, estimated at \$2b; a government review and oversupply made FY26 challenging.
- Expanded our range with NZ grown genetics; progressing talks with large clinic chains.
- Delivered cost reduced by close to 50%.

Estimated market size





United Kingdom is the fastest growing market

- Fastest growing market: prescriptions doubled in the past year; estimated at \$400m.
- July 2026: sales and distribution agreement signed with a leading UK clinic chain.
- Working with NZ cultivators to bring Rua's genetics to the UK.

~\$10m

Expected sales over initial two-year term



Czechia: We are one of the early entrants

- April 2025 reform allowed GPs to prescribe medicinal cannabis.
- First product launched through distribution partner Motagon.
- Early-stage market (~\$10m); modest revenue expected to build through FY27.

Sept 2025

First product launched



Canada: A first foothold for Rua genetics

- April 2026: first known legal export of live cannabis genetics from New Zealand.
- Four varieties shipped as clones to Apollo Green in Ontario, establishing a genetic bank.
- Creates further options for distribution and revenue.

\$5–6b

Estimated annual adult-use market

We continue to support 52 patients per month through our Compassionate Access Programme

52

patients supported each month



Our Scholarship Programme is inspiring rangatahi

In FY26 we awarded 14 scholarships to local rangatahi

14

Scholarships in FY26

67

Recipients since 2020

8

School trips funded

3

Internships



Rua's FY26 GHG report

Te ripoata GHG o Rua mo FY26

19% ↓

Scope 1 and 2 emissions reduced by 19% (FY25: 39, FY26: 32 tCO₂-e)


14% ↓

Scope 1 emissions reduced by 14%, with a smaller vehicle fleet

22% ↓

Scope 2 emissions reduced by 22%, as NZ's grid emissions fell

Scope 1 and 2 emissions (tCO₂-e)



The next generation of Rua products



INITIAL PHASE

MDMA distribution

PharmAla agreement: Rua imports, distributes and sells pharmaceutical-grade MDMA in Aotearoa. Medsafe has approved two psychiatrists to prescribe for PTSD. Capital-light.



RESEARCH PROGRAMME

Tū Wairua

Psilocybin-containing mushrooms for methamphetamine addiction, led by the Rangiwhao Marae community. Rua contributes cultivation and regulatory capability.



RESEARCH PROGRAMME

Wairuakōhu

Radula liverwort, native to Aotearoa, produces compounds understood to act on cannabinoid receptors. Partners include IO Limited.



RESEARCH PROGRAMME

Cytisine from kōwhai

A native source of an established smoking-cessation medicine, with a substantial clinical evidence base including New Zealand-led trials.

No revenue from the research programmes is assumed in FY27 or FY28. Rua contributes capability, not capital.

Our plans for FY27 are to continue growing sales



UK DISTRIBUTION AGREEMENT

**~\$10m over two
years**



NEW PRODUCTS

**Five new approvals
in Aotearoa NZ**



NEW MARKETS

Canada

03

FY26 financial commentary

Nga korero mo nga putea



Profit & loss

Nga korero mo nga putea

Rua's annual financial results for the year ended 30 June 2026.

\$2.6m

Revenue from customers

\$2.9m

Total revenue and other income

-\$3.4m

Loss before tax

Strong revenue growth

Balance sheet

Nga korero mo nga putea

Rua's annual financial results for the year ended 30 June 2026.

\$534k

Cash and investments

\$7.17m

Total assets

\$2.92m

Total liabilities

\$4.25m

Net assets

Rua requires further capital

Cashflow

Nga korero mo nga putea

Rua's annual financial results for the year ended 30 June 2026.

\$2.96m

Net cash outflow from operating
activities

\$0.01m

Net cash inflow from investing
activities

\$3.24m


Net cash inflow from financing
activities

Investing in growth

Operating loss is narrowing

Nga korero mo nga putea


Operating loss before net financing costs



Sales revenue is growing

Nga korero mo nga putea

Annual revenue from customers



An aerial photograph of a coastline. The top half of the image shows the ocean with waves breaking onto a sandy beach. The waves are white and foamy, contrasting with the dark blue-green water. The beach is a light tan color. The bottom half of the image shows a rocky shoreline with dark, jagged rocks. Some green vegetation is visible on the right side of the rocks.

04

Shareholder questions

Nga patai a nga kaipupuri hea



05

Ordinary resolutions

Whakataunga noa



Resolution One

That the Board be authorised to fix the auditor's remuneration.

Resolution Two

That Anna Stove be re-elected
as a Director of Rua



Resolution Three

That Panapa Ehau be re-elected as a Director of Rua



Resolution Four

That Antony Barclay be re-elected as a Director of Rua



Resolution Five

That Qi (Keith) Zhou be elected as a Director of Rua

- Nominated within the Director Nomination Period
- Would not be an Independent Director if elected
- The Board supports his election



Resolution Six

That the Directors are authorised to issue New Shares if required

- Up to 69,635,032 shares
- At a price of not less than \$0.03 per share
- At any time during the 12 months following approval



06

General business

Nga take hakirikiri

The image shows a vast field of green hemp plants, likely in a cultivation facility, with rows of plants stretching into the distance. The scene is bathed in the warm, golden light of a sunset or sunrise, with the sun low on the horizon behind a range of hills. The overall atmosphere is serene and natural, emphasizing the organic nature of the bioscience. The logo for IRUA Bioscience is centered in the upper half of the image. The text 'IRUA' is in a large, stylized, teal-colored font, and 'BIOSCIENCE' is in a smaller, simpler, teal-colored font directly below it.

IRUA

BIOSCIENCE